OR WAIT null SECS
March 25, 2022
Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
March 23, 2022
It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.
March 15, 2022
Mazur talks about his commitment to drug development and what it takes to succeed in the industry today.
March 10, 2022
Mary Jo Struttmann, executive director of alliance management for Astellas discusses how to form strategic partnerships to bring new drugs to market and how to navigate partnerships, alliance dynamics, and potential challenges in 2022 and beyond.
March 07, 2022
Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.
February 18, 2022
Assessing the road ahead for Chinese biotech.
February 17, 2022
Licensing deals, strategy, and COVID among factors to consider for companies entering Chinese pharma M&A.
February 15, 2022
Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.
With a strong pharma background that includes bringing non-US biotechs stateside in the rare diseases space, Rami Levin, CEO of Saniona, talks about the importance of growing his company’s business and his dedication to that mission.
January 12, 2022
Biopharma must step up amidst growing oncology market.
